Feedback networks between microRNAs and epigenetic modifications in urological tumors

Epigenetics

Volumn 7, Issue 4, 2012, Pages 315-325

  Liep, Julia ^a,b   Rabien, Anja ^a   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

DNA methylation; Epigenetics; Histone modification; MicroRNA; Urological tumors

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 126; MICRORNA 143; MICRORNA 182; MICRORNA 200; MICRORNA 205; MICRORNA 9; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CARCINOGENESIS; CELL TRANSFORMATION; CHROMATIN; DEACETYLATION; DNA METHYLATION; EPIGENETICS; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; METASTASIS; MUSCLE DEVELOPMENT; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR GROWTH; URINARY TRACT TUMOR;

EID: 84860557757     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.19464     Document Type: Article

References (141)

1. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 2011; 585:2087-99. PMID:20708002; http://dx.doi.org/10.1016/j.feb-slet.2010.08.009.
2. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet 2010; 70:87-99. PMID:20920746; http://dx.doi.org/10.1016/B978-0-12-380866-0.60004-6.
3. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res 2011; 717:77-84. PMID:21420983; http://dx.doi.org/10.1016/j.mrfmmm.2011.03.008.
4. Weber W. Cancer epigenetics. Prog Mol Biol Transl Sci 2010; 95:299-349. PMID:21075335; http://dx.doi.org/10.1016/B978-0-12-385071-3.00010-1.
5. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60:753-66. PMID:21719191; http://dx.doi.org/10.1016/j.eururo.2011.06.035.
6. Enokida H, Nakagawa M. Epigenetics in bladder cancer. Int J Clin Oncol 2008; 13:298-307. PMID:18704629; http://dx.doi.org/10.1007/s10147-008-0811-1.
7. Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010; 7:286-97. PMID:20368743; http://dx.doi.org/10.1038/nrurol.2010.45.
8. Wiklund ED, Kjems J, Clark SJ. Epigenetic architecture and miRNA: reciprocal regulators. Epigenomics 2010; 2:823-40. PMID:22122085; http://dx.doi.org/10.2217/epi.10.51.
9. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010; 1799:694-701; PMID:20493980.
10. Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci 2010; 101:2309-15. PMID:20726859; http://dx.doi.org/10.1111/j.1349-7006.2010.01683.x.
11. Iacobuzio-Donahue CA. Epigenetic changes in cancer. Annu Rev Pathol 2009; 4:229-49. PMID:18840073; http://dx.doi.org/10.1146/annurev.pathol.3.121806.151442.
12. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-9. PMID:21386836; http://dx.doi.org/10.1038/nm.2305.
13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-54. PMID:8252621; http://dx.doi.org/10.1016/0092-8674(93)90529-Y.
14. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294:853-8. PMID:11679670;http://dx.doi.org/10.1126/science.1064921.
15. Davis-Dusenbery BN, Hata A. Mechanisms of control of microRNA biogenesis. J Biochem 2010; 148:381-92. PMID:20833630.
16. Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol 2011; 676:3-22; PMID:20931386; http://dx.doi.org/10.1007/978-1-60761-863-8_1.
17. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004; 32:109-11. PMID:14681370; http://dx.doi.org/10.1093/nar/gkh023.
18. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36:154-8. PMID:17991681; http://dx.doi.org/10.1093/nar/gkm952.
19. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34:140-4. PMID:16381832; http://dx.doi.org/10.1093/nar/gkj112.
20. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39:152-7. PMID:21037258; http://dx.doi.org/10.1093/nar/gkq1027.
21. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20. PMID:15652477; http://dx.doi.org/10.1016/j.cell.2004.12.035.
22. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769-73. PMID:15685193; http://dx.doi.org/10.1038/nature03315.
23. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101:2999-3004. PMID:14973191; http://dx.doi.org/10.1073/pnas.0307323101.
24. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37:766-70 PMID:15965474; http://dx.doi.org/10.1038/ng1590.
25. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8. PMID:15944708; http://dx.doi.org/10.1038/nature03702
26. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61. PMID:16461460; http://dx.doi.org/10.1073/pnas.0510565103.
27. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69. PMID:16557279; http://dx.doi.org/10.1038/nrc1840.
28. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67:6130-5. PMID:17616669; http://dx.doi.org/10.1158/0008-5472.CAN-07-0533.
29. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68:6162-70. PMID:18676839; http://dx.doi.org/10.1158/0008-5472.CAN-08-0144.
30. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80 PMID:11498575; http://dx.doi.org/10.1126/science.1063127.
31. Yokochi T, Robertson KD. Preferential methylation of unmethylated DNA by Mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem 2002; 277:11735-45. PMID:11821381; http://dx.doi.org/10.1074/jbc.M106590200.
32. Goll MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh CL, Zhang X, et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006; 311:395-8. PMID:16424344; http://dx.doi. org/10.1126/science.1120976.
33. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16:6-21 PMID:11782440; http://dx.doi.org/10.1101/gad.947102.
34. Ballestar E, Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol 2005; 83:374-84 PMID:15959563; http://dx.doi.org/10.1139/o05-035.
35. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007; 14:1008-16 PMID:17984963; http://dx.doi.org/10.1038/nsmb1337.
36. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004; 116:259-72. PMID:14744436; http://dx.doi.org/10.1016/S0092-8674(04)00044-3.
37. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005; 14:85-92 PMID:15809277.http://dx.doi.org/10.1093/hmg/ddi106.
38. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64:435-59. PMID:10839822; http://dx.doi.org/10.1128/MMBR.64.2.435-59.2000.
39. Lee JS, Smith E, Shilatifard A. The language of histone crosstalk. Cell 2010; 142:682-5. PMID:20813257; http://dx.doi.org/10.1016/j.cell.2010.08.011.
40. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59. PMID:18337604; http://dx.doi.org/10.1056/NEJMra072067.
41. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruïne AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008; 1785:133-55. PMID:18187049.
42. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006; 94:179-83. PMID:16404435; http://dx.doi.org/10.1038/sj.bjc.6602918.
43. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55:4531-5; PMID:7553622.
44. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564-9. PMID:10749912; http://dx.doi.org/10.1093/jnci/92.7.564.
45. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57:808-11. PMID:9041175.
46. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007; 13:2046-53. PMID:17404085; http://dx.doi.org/10.1158/1078-0432.CCR-06-2476.
47. Park JY. Promoter hypermethylation in prostate cancer. Cancer Control 2010; 17:245-55. PMID:20861812.
48. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999; 39:166-74. PMID:10334105; http://dx.doi.org/10.1002/(SICI)1097-0045(19990515)39:3166::AID-PROS43.0.CO;2-J.
49. Jürgens B, Schmitz-Dräger BJ, Schulz WA. Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res 1996; 56:5698-703 PMID:8971178.
50. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21:5400-13. PMID:12154403; http://dx.doi.org/10.1038/sj.onc.1205651.
51. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300:455 PMID:12702868; http://dx.doi.org/10.1126/sci-ence.1083557.
52. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14:65-76. PMID:15809275; http://dx.doi.org/10.1093/hmg/ddi113.
53. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation atLys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400. PMID:15765097; http://dx.doi.org/10.1038/ng1531.
54. Bianco T, Hussey D, Dobrovic A. Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation. Hum Mutat 1999; 14:289-93. PMID:10502775; http://dx.doi.org/10.1002/(SICI)1098-1004(199910)14:4289::AID-HUMU33.0.CO;2-A.
55. Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation and histone acetylation. Cancer Res 2003; 63:2164-71. PMID:12727835.
56. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7. PMID:9916800; http://dx.doi.org/10.1038/5047.
57. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006; 5:2220-2. PMID:17012846; http://dx.doi.org/10.4161/cc.5.19.3340.
58. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microR-NA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9:435-43. PMID:16766263; http://dx.doi.org/10.1016/j.ccr.2006.04.020.
59. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67:1424-9 PMID:17308079; http://dx.doi.org/10.1158/0008-5472.CAN-06-4218.
60. Dudziec E, Miah S, Choudhry HM, Owen HC, Blizard S, Glover M, et al. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 2011; 17:1287-96. PMID:21138856; http://dx.doi.org/10.1158/1078-0432.CCR-10-2017.
61. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125:2737-43. PMID:19521961; http://dx.doi.org/10.1002/ijc.24638.
62. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105:13556-61. PMID:18768788; http://dx.doi.org/10.1073/pnas.0803055105.
63. Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martinsubero JI, Cordeu L, Gárate L, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009; 69:4443-53. PMID:19435910; http://dx.doi.org/10.1158/0008-5472.CAN-08-4025.
64. Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010; 70:1441-8. PMID:20124485; http://dx.doi.org/10.1158/0008-5472.CAN-09-3289.
65. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104:15805-10. PMID:17890317; http://dx.doi.org/10.1073/pnas.0707628104.
66. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113:6411-8. PMID:19211935; http://dx.doi.org/10.1182/blood-2008-07-170589.
67. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008; 14:872-7. PMID:18367714; http://dx.doi.org/10.1261/rna.972008.
68. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51:881-90. PMID:20146264.
69. + T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010; 184:6773-81. PMID:20483747; http://dx.doi.org/10.4049/jimmu-nol.0904060.
70. Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ, et al. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 2009; 101:699-706. PMID:19638978; http://dx.doi.org/10.1038/sj.bjc.6605195.
71. Benetti R, Gonzalo S, Jaco I, Muñoz P, Gonzalez S, Schoeftner S, et al. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol 2008; 15:268-79. PMID:18311151; http://dx.doi.org/10.1038/nsmb.1399
72. Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG, et al. MicroRNAsonic stem cells. Nat Struct Mol Biol 2008; 15:259-67. PMID:18311153; http://dx.doi.org/10.1038/nsmb.1391.
73. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38:228-33. PMID:16380711; http://dx.doi.org/10.1038/ng1725.
74. Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69:2623-9. PMID:19258506; http://dx.doi.org/10.1158/0008-5472.CAN-08-3114.
75. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28:1714-24. PMID:19252524; http://dx.doi.org/10.1038/onc.2009.19.
76. Tuddenham L, Wheeler G, Ntounia-Fousara S, Waters J, Hajihosseini MK, Clark I, et al. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett 2006; 580:4214-7. PMID:16828749; http://dx.doi.org/10.1016/j.febslet.2006.06.080.
77. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010; 127:1363-72. PMID:20073067; http://dx.doi.org/10.1002/ijc.25162.
78. Yin R, Zhang S, Wu Y, Fan X, Jiang F, Zhang Z, et al. microRNA-145 suppresses lung adenocarcinomainitiating cell proliferation by targeting OCT4. Oncol Rep 2011; 25:1747-54. PMID:21479367.
79. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127:2804-14. PMID:21351259; http://dx.doi.org/10.1002/ijc.25284.
80. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011; 32:772-8. PMID:21349819; http://dx.doi.org/10.1093/carcin/bgr036.
81. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, et al. The functional significance of microR-NA-145 in prostate cancer. Br J Cancer 2010; 103:256-64. PMID:20588276; http://dx.doi.org/10.1038/sj.bjc.6605742.
82. Hulf T, Sibbritt T, Wiklund ED, Bert S, Strbenac D, Statham AL, et al. Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC Genomics 2011; 12:54. PMID:21255435; http://dx.doi.org/10.1186/1471-2164-12-54.
83. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through downregulation of protein kinase Cepsilon. Cancer Res 2009; 69:2287-95. PMID:19244118; http://dx.doi.org/10.1158/0008-5472.CAN-08-2894.
84. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128:1327-34. PMID:20473948; http://dx.doi.org/10.1002/ijc.25461.
85. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010; 1:105. PMID:21368878; http://dx.doi.org/10.1038/cddis.2010.85.
86. Tarasov Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6:1586-93. PMID:17554199; http://dx.doi.org/10.4161/cc.6.13.4436.
87. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52. PMID:17540599; http://dx.doi.org/10.1016/j.mol-cel.2007.05.010.
88. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17:193-9. PMID:19461653; http://dx.doi.org/10.1038/cdd.2009.56.
89. Hermeking H. MiR-34a and p53. Cell Cycle 2009; 8:1308. PMID:19342875; http://dx.doi.org/10.4161/cc.8.9.8511.
90. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7:2591-600. PMID:18719384; http://dx.doi.org/10.4161/cc.7.16.6533.
91. Vogt M, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011; 458:313-22. PMID:21225432; http://dx.doi.org/10.1007/s00428-010-1030-5.
92. Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA, Ulmert D, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010; 127:2768-76. PMID:21351256; http://dx.doi.org/10.1002/ijc.25269.
93. Noonan EJ, Place RF, Basak S, Pookot D, Li LC. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 2010; 1:349-58. PMID:20948989.
94. Wedel SA, Sparatore A, Soldato PD, Al-Batran SE, Atmaca A, Juengel E, et al. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J Cell Mol Med 2008; 12:2457-66. PMID:18266964; http://dx.doi.org/10.1111/j.1582-4934.2008.00271.x.
95. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14:155-64. PMID:15196462; http://dx.doi.org/10.1016/j.gde.2004.02.001.
96. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439:871-4. PMID:16357870; http://dx.doi.org/10.1038/nature04431.
97. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322:1695-9. PMID:19008416; http://dx.doi.org/10.1126/science.1165395.
98. Yoshitomi T, Kawakami K, Enokida H, Chiyomaru T, Kagara I, Tatarano S, et al. Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines. Oncol Rep 2011; 25:1661-8. PMID:21479368.
99. Tsai KW, Kao HW, Chen HC, Chen SJ, Lin WC. Epigenetic control of the expression of a primatespecific microRNA cluster in human cancer cells. Epigenetics 2009; 4:587-92. PMID:19923923; http://dx.doi.org/10.4161/epi.4.8.10230.
100. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypoand hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86. PMID:19151715; http://dx.doi.org/10.1038/ng.298
101. Jäger T, Becker M, Eisenhardt A, Tilki D, Tötsch M, Schmid KW, et al. The prognostic value of cadherin switch in bladder cancer. Oncol Rep 2010; 23:1125-32. PMID:20204300.
102. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22:894-907. PMID:18381893; http://dx.doi.org/10.1101/gad.1640608.
103. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283:14910-4. PMID:18411277; http://dx.doi.org/10.1074/jbc.C800074200.
104. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601. PMID:18376396; http://dx.doi.org/10.1038/ncb1722.
105. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, et al. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun 2008; 377:136-40. PMID:18834857; http://dx.doi.org/10.1016/j.bbrc.2008.09.089.
106. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147-52. PMID:18185580; http://dx.doi.org/10.1038/nature06487.
107. Shen WF, Hu YL, Uttarwar L, Passegue E, Largman C. MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol Cell Biol 2008; 28:4609-19 PMID:18474618; http://dx.doi.org/10.1128/MCB.01652-07.
108. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009; 379:726-31 PMID:19116145; http://dx.doi.org/10.1016/j.bbrc.2008.12.098.
109. Kim YK, Kim VN. Processing of intronic microRNAs. EMBO J 2007; 26:775-83. PMID:17255951; http://dx.doi.org/10.1038/sj.emboj.7601512.
110. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011; 6:18286. PMID:21464941; http://dx.doi.org/10.1371/journal.pone.0018286.
111. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, et al. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 2011; 6:20341. PMID:21647377; http://dx.doi.org/10.1371/journal.pone.0020341.
112. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGFbeta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22:1686-98. PMID:21411626; http://dx.doi.org/10.1091/mbc.E11-02-0103.
113. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29:5724-8. PMID:20676129; http://dx.doi.org/10.1038/onc.2010.305.
114. López-Lago MA, Thodima VJ, Guttapalli A, Chan T, Heguy A, Molina AM, et al. Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. Cancer Res 2010; 70:9682-92. PMID:20952505; http://dx.doi.org/10.1158/0008-5472.CAN-10-2279.
115. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, et al. The tumoursuppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 2011; 104:808-18. PMID:21304530; http://dx.doi.org/10.1038/bjc.2011.23.
116. Yawakami K, Enokida H, Chiyomaru T, Tatarano S, oshino H, Kagara I, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2011; 48:827-36. PMID:21745735; http://dx.doi.org/10.1016/j.ejca.2011.06.030.
117. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant downregulation of miR-141 and miR-200c. J Pathol 2008; 216:418-27. PMID:18925646; http://dx.doi.org/10.1002/path.2437.
118. Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008; 214:17-24. PMID:17948228; http://dx.doi.org/10.1002/path.2251.
119. Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, et al. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NFkappaB1. FEBS J 2009; 276:5537-46. PMID:19702828; http://dx.doi.org/10.1111/j.1742-4658.2009.07237.x.
120. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007; 67:1419-23. PMID:17308078; http://dx.doi.org/10.1158/0008-5472.CAN-06-4074.
121. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007; 67:10117-22. PMID:17974952; http://dx.doi.org/10.1158/0008-5472.CAN-07-2544.
122. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, et al. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res 2011; 71:5646-58. PMID:21734013; http://dx.doi.org/10.1158/0008-5472.CAN-11-1076.
123. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68:5049-58. PMID:18593903; http://dx.doi.org/10.1158/0008-5472.CAN-07-6655.
124. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699-707. PMID:17875710; http://dx.doi.org/10.1158/0008-5472.CAN-07-1936.
125. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68:4123-32. PMID:18519671; http://dx.doi.org/10.1158/0008-5472.CAN-08-0325.
126. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009; 9:293-301. PMID:19407485; http://dx.doi.org/10.1159/000186051.
127. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, et al. Methylation-mediated silencing and tumour suppressive function of hsamiR-124 in cervical cancer. Mol Cancer 2010; 9:167. PMID:20579385; http://dx.doi.org/10.1186/1476-4598-9-167.
128. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68:2094-105. PMID:18381414; http://dx.doi.org/10.1158/0008-5472.CAN-07-5194.
129. Tsai KW, Hu LY, Wu CW, Li SC, Lai CH, Kao HW, et al. Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer 2010; 49:969-80. PMID:20662076; http://dx.doi.org/10.1002/gcc.20804.
130. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 2010; 5:8697. PMID:20084174; http://dx.doi.org/10.1371/journal.pone.0008697.
131. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11:1487-95. PMID:19935649; http://dx.doi.org/10.1038/ncb1998.
132. Neves R, Scheel C, Weinhold S, Honisch E, Iwaniuk KM, Trompeter HI, et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 2010; 3:219. PMID:20682048; http://dx.doi.org/10.1186/1756-0500-3-219.
133. Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, Santos J, Calin GA, Cigudosa JC, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13:496-506. PMID:18538733; http://dx.doi.org/10.1016/j.ccr.2008.04.018.
134. Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ ETO oncoprotein. Cancer Cell 2007; 12:457-66. PMID:17996649; http://dx.doi.org/10.1016/j.ccr.2007.09.020.
135. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008; 27:3880-8. PMID:18264139; http://dx.doi.org/10.1038/onc.2008.10.
136. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleu-kin-6 in malignant human cholangiocytes. Oncogene 2008; 27:378-86. PMID:17621267; http://dx.doi.org/10.1038/sj.onc.1210648.
137. Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, Kanai Y, et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 2009; 28:2738-44. PMID:19503096; http://dx.doi.org/10.1038/onc.2009.140.
138. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28:4065-74. PMID:19734943; http://dx.doi.org/10.1038/onc.2009.274.
139. Wong CF, Tellam RL. MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 2008; 283:9836-43. PMID:18281287; http://dx.doi.org/10.1074/jbc.M709614200.
140. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112:4202-12. PMID:18713946; http://dx.doi.org/10.1182/blood-2008-03-147645.
141. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell 2009; 36:61-74. PMID:19818710; http://dx.doi.org/10.1016/j.molcel.2009.08.008.